Quidel
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 1.7b | 1.7b | 3.3b | 3.0b | 2.7b | 2.8b | 3.0b |
| % growth | 211 % | 2 % | 92 % | (8 %) | (9 %) | 3 % | 5 % |
| EBITDA | 1.1b | 916m | 1.1b | 691m | 544m | 661m | 718m |
| % EBITDA margin | 64 % | 54 % | 34 % | 23 % | 20 % | 24 % | 24 % |
| Profit | 810m | 704m | 549m | (10.1m) | (1.3b) | (7.5m) | 45.4m |
| % profit margin | 49 % | 41 % | 17 % | - | (47 %) | - | 2 % |
| EV / revenue | 4.3x | 2.8x | 2.4x | 2.4x | 1.9x | 1.7x | 1.5x |
| EV / EBITDA | 6.6x | 5.2x | 7.2x | 10.4x | 9.3x | 7.2x | 6.2x |
| R&D budget | 84.3m | 95.7m | 191m | 247m | - | - | - |
| R&D % of revenue | 5 % | 6 % | 6 % | 8 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
$635k | Grant | ||
| Total Funding | €577k | ||
Recent News about Quidel
EditQuidel Corporation, established in 1979, is a prominent player in the medical diagnostics industry. The company specializes in developing, manufacturing, and marketing diagnostic testing solutions. Quidel's product portfolio includes a wide range of diagnostic tests that are used to detect various diseases and conditions. These products are primarily used by healthcare professionals in hospitals, clinics, and laboratories.
Quidel operates in the global healthcare market, with a strong focus on infectious diseases, reproductive health, bone health, and virology. The company has established itself as a leader in several diagnostic categories, including lateral flow tests, direct fluorescent antibody (DFA) tests, microtiter plate-based tests, fluorescent immunoassays, and molecular diagnostic products.
The company's business model revolves around the development and commercialization of innovative diagnostic tests. Quidel invests heavily in research and development to create new products and improve existing ones. The company generates revenue by selling its diagnostic tests and related products to healthcare providers and institutions. Additionally, Quidel has expanded its product base through strategic acquisitions, further enhancing its market presence and product offerings.
Quidel's recent achievements include the development of a rapid antigen test for detecting COVID-19, which received emergency use authorization from the FDA. This test is notable for being faster, cheaper, and simpler than traditional diagnostic methods, making it a valuable tool in managing the pandemic.
In summary, Quidel Corporation is a key player in the medical diagnostics industry, providing innovative and reliable diagnostic solutions to healthcare professionals worldwide. The company's commitment to research and development, coupled with its strategic acquisitions, has positioned it as a leader in the market.
Keywords: diagnostics, healthcare, infectious diseases, reproductive health, virology, lateral flow tests, fluorescent immunoassays, molecular diagnostics, COVID-19 antigen test, FDA approval.
Tech stack
Investments by Quidel
Edit
